Company intelligence / Profile preview
InThera
Schlieren, Zurich, Switzerlandinthera.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
InThera is a Swiss biotechnology company focused on developing a new class of low-molecular-weight drugs to treat solid tumors. The company specializes in targeting protein-protein interactions, specifically focusing on transcription factors that are traditionally considered undruggable. Their lead programs are designed to inhibit the Signal transducer and activator of transcription 3 (STAT3) pathway, which is frequently overactivated in various cancers. By utilizing a proprietary technology platform, InThera aims to provide highly selective oral therapies for patients with limited treatment options.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on InThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InThera.